Mycofenolaatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofenolaatmofetil Accord, is an antimetabolite immunosuppressant presented as an injection for intravenous use. It is used to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis.

GNH USA supplies Mycofenolaatmofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil acts on the immune system to inhibit lymphocyte proliferation, making it valuable in transplant and autoimmune disease management. - Organ transplant rejection: helps prevent acute and chronic rejection by suppressing immune response. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Other autoimmune conditions: may be employed off‑label for diseases such as vasculitis where immune suppression is required.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools that may lead to dehydration. - Headache: transient cranial discomfort. - Infection risk: increased susceptibility to bacterial, viral, and fungal infections. - Leukopenia: reduced white blood cell count. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Malignancy: heightened risk of lymphoproliferative disorders. - Hepatic failure: elevated liver enzymes and possible liver injury. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease. - Bone marrow suppression: pancytopenia requiring medical intervention. - Gastrointestinal perforation: rare but life‑threatening abdominal events.

Careful monitoring and patient counseling are essential when using Mycofenolaatmofetil Accord. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy in patients with impaired kidney function. - Screen for infections: test for latent tuberculosis, hepatitis B/C before initiation. - Avoid in pregnancy: teratogenic and classified as Pregnancy Category X. - Avoid breastfeeding: drug is excreted in breast milk and may harm the infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mycophenolate Mofetil can interact with several medications, affecting efficacy or safety.

Major Interactions (Avoid): - Live vaccines: increased risk of severe infection. - Other antimetabolites (e.g., azathioprine): additive bone marrow suppression. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce mycophenolate exposure.

Moderate Interactions (Monitor Closely): - Calcineurin inhibitors (cyclosporine, tacrolimus): may raise mycophenolate levels, requiring dose adjustment. - Antifungal agents (ketoconazole, itraconazole): can increase drug concentration. - Hormonal contraceptives: may reduce efficacy, advise alternative contraception.